B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

NCT07193628 | Recruiting Phase 1 DMC

• 1 other identifier: 2025-0424
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

This study is an investigator-initiated, open-label Phase I clinical trial designed to evaluate the safety and efficacy of EPC-003 fully human anti-B7H3/IL13Ra2 armored Chimeric Antigen Receptor T-Cell Therapy (CAR-T) cell injection in patients with recurrent or refractory glioblastoma. Approximately 14 patients with relapsed or refractory glioblastoma are planned to be enrolled in this trial. During the screening period (Days -28 to -15), subjects will undergo relevant examinations or observations to confirm the disease status, treatment history, and other related information. Subjects who meet the screening criteria will be enrolled in the clinical trial to receive EPC-003 treatment. Specifically, they will receive intraventricular injection of EPC-003 via Ommaya reservoir on Day 0 (D0), Day 7 (D7), Day 14 (D14), Day 21 (D21), Day 28 (D28), and Day 35 (D35), once a week, totaling 6 administrations. All CAR-T cell infusions will be delivered via intraventricular injection. This trial comprises two phases: the first phase is the dose-escalation phase, and the second phase is the dose-expansion phase.

Conditions

Refractory Glioblastoma; Recurrent Glioblastoma

Keywords

refractory glioblastoma; recurrent glioblastoma; Immunotherapy, Adoptive; Receptors, Chimeric Antigen; Interleukin-13 Receptor alpha2 Subunit

Outcome Measures

Primary Outcomes (1)

• The incidence of grade 3-4 adverse events (AEs) related to B7H3/IL13Ra2 CAR-T therapy.

  The incidence of grade 3-4 adverse events (AEs) related to B7H3/IL13Ra2 CAR-T therapy assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria .

  28 days after first infusion of CAR-T treatment

Secondary Outcomes (5)

• Objective response rate (ORR) within 12 months of the follow-up period

  From enrollment to the end of treatment at 1 year

• Duration of response (DOR) within 12 months of the follow-up period

  From enrollment to the end of treatment at 1 year

• Disease control rate (DCR) within 12 months of the follow-up period

  From enrollment to the end of treatment at 1 year

• Progression-Free Survival (PFS) within 12 months of the follow-up period

  From enrollment to the end of treatment at 1 year

• Overall Survival (OS) within 12 months of the follow-up period

  From enrollment to the end of treatment at 1 year

Study Arms (4)

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Dose Level 1 Treatment Group

EXPERIMENTAL

2.5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects.

Biological: EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1)

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Dose Level 2 Treatment Group

EXPERIMENTAL

5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects.

Biological: EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2)

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Dose Level 3 Treatment Group

EXPERIMENTAL

10 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects.

Biological: EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3)

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Dose Level 4 Treatment Group

EXPERIMENTAL

20 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects.

Biological: EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 4)

Interventions

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1) BIOLOGICAL

2.5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Dose Level 1 Treatment Group

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2) BIOLOGICAL

5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Dose Level 2 Treatment Group

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3) BIOLOGICAL

10 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Dose Level 3 Treatment Group

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 4) BIOLOGICAL

20 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.

EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Dose Level 4 Treatment Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• : Agree to comply with the trial treatment plan and visit schedule, voluntarily enroll in the trial, and sign the informed consent form in writing.
• : On the day of signing the informed consent form, the subject shall be aged between 18 and 75 years inclusive, with no restriction on gender.
• : Karnofsky Performance Status (KPS) score ≥ 60%
• : Patients with B7H3- and/or IL13Ra2-positive recurrent or refractory glioblastoma confirmed by histopathology and/or cytology, meeting the following criteria: The positive expression rate of B7H3 \> 30%; The positive expression rate of IL13RA2 \> 30%; Disease progression or recurrence after standard treatment (postoperative radiotherapy combined with concurrent and adjuvant chemotherapy with temozolomide); The subject has at least one measurable lesion (based on RANO criteria, with mutually perpendicular diameters both ≥ 10mm).
• : Expected survival time ≥ 12 weeks;
• : Subjects must have adequate organ function, meeting the following laboratory test criteria: Bone Marrow Function: Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹/L; Platelet Count (PLT) ≥ 100×10⁹/L; Absolute Lymphocyte Count ≥ 0.3×10⁹/L; Hemoglobin (HGB) ≥ 8.0 g/dL. Liver function: Serum total bilirubin (T-Bil) ≤ 1.5 × upper limit of normal (ULN); for patients without liver involvement, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN; for patients with liver involvement, ALT and AST ≤ 5 × ULN; Renal function: Serum creatinine ≤ 1.6 × ULN, or creatinine clearance (Ccr) ≥ 50 mL/min (calculated according to the Cockcroft-Gault formula); Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; Left ventricular ejection fraction \> 50%.
• : Male subjects with reproductive potential and female subjects of childbearing age must agree to use effective contraceptive measures from the time of signing the informed consent form until 1 year after the last administration of the trial drug. For female subjects of childbearing age, the pregnancy test result within ≤7 days before the administration of the trial drug must be negative.

You may not qualify if:

• : The lesion is located in the posterior fossa structures such as the cerebellum, pons, and medulla oblongata.
• : Complicated with meningeal metastasis or detectable malignant tumor cells in cerebrospinal fluid.
• : Presence of epilepsy and/or high intracranial pressure that cannot be controlled or stabilized with medication.
• : Subjects with current comorbid other central nervous system (CNS) diseases or a history of CNS diseases within 6 months prior to screening, such as uncontrolled cerebrovascular accident, transient ischemic attack, stroke, and any other autoimmune diseases involving the central nervous system.
• : Subjects who have been diagnosed with other malignant tumors within 5 years prior to screening, excluding adequately treated carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical treatment, and ductal carcinoma in situ of the breast after radical treatment.
• : Subjects who have previously received treatment targeting B7H3/IL13Ra2.
• : Subjects who have previously received gene therapy or cell therapy.
• : Subjects who have a history of long-term use of immunosuppressive drugs or high-dose steroid hormones; inhaled hormones used for the treatment of chronic bronchial inflammation or asthma are not affected.
• : Subjects who have previously received allogeneic hematopoietic stem cell transplantation; or those who are eligible for and agree to undergo autologous hematopoietic stem cell transplantation.
• : Uncontrolled active bacterial, viral, or fungal infection.
• : Any unstable systemic disease, including but not limited to cardiovascular diseases such as unstable angina pectoris, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association \[NYHA\] classification ≥ III), severe arrhythmias requiring medication, as well as pulmonary, hepatic, renal, digestive system, or metabolic diseases.
• : Subjects who have received oral anticoagulant therapy within 1 week prior to CAR-T cell infusion.
• : Subjects who have received anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, TTfield therapy, investigational trial drugs, and other anti-tumor treatments) within 4 weeks prior to cell infusion or within 5 half-lives of the drug (whichever is shorter), and/or have not recovered from toxic reactions (recovery to CTCAE Version 5.0 grade ≤ 1) (except for alopecia; peripheral neurotoxicity with grade ≤ 2 is acceptable).
• : Subjects who have received radiotherapy within 12 weeks prior to cell infusion (those with progressive disease outside the irradiated field or those in whom pseudo-progression after radiotherapy/chemotherapy can be excluded are eligible for enrollment).
• : Subjects who have undergone major surgery or significant traumatic injury within 4 weeks prior to informed consent, or have not recovered from the side effects of surgery, or plan to undergo major surgery during the trial period.

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

Study Sites (1)

the Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 210000, China

RECRUITING

MeSH Terms

Conditions

Glioblastoma

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Officials

• Feng Yan, MD & PhD

  Department of Neurosurgery, the Second Affiliated Hospital of Zhejiang University School of Medicine

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Feng Yan, MD, PhD

CONTACT

86-19700700159; yan.feng7@163.com

Shuyu Zheng, MD

CONTACT

86-19700700159; 2322125@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2025
• First Posted: September 26, 2025
• Study Start: September 26, 2025
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: November 18, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)